HENDERSON, Nev., Jan. 20, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, which will focus on Volition's Nu.Q® Vet commercial strategy.

The webinar takes place on Thursday, January 26^th at 12 noon U.S. Eastern Time and will include updates from Dr. Tom Butera (Chief Executive Officer) and Dr. Heather Wilson Robles (Chief Medical Officer) of Volition Veterinary Diagnostics Development LLC, and Gael Forterre, Volition's Chief Commercial Officer.

The panel and Q&A event is being hosted by Soo Romanoff, Managing Director of Healthcare at Edison Group. It follows the release this week of 'Vetting the pet health opportunity', an insights report on Volition.

Event Details:

Title: Nu.Q® Vet Commercial Strategy

Date: Thursday, January 26, 2023

Time: 12 noon Eastern, U.S

Register at: https://edisongroup.zoom.us/webinar/register/WN_TjeTdVOLQry4PpBJyzLCpg

Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC said: "The Nu.Q® Vet Cancer Test is a simple, cost effective, easy to use blood test for screening older or 'at risk' dogs. It was developed with the goal of providing an accessible and affordable screening test to aid early detection.

"We are now embarking on a pivotal phase for Volition as we continue to roll out our Nu.Q® technology within the companion animal healthcare sector and capitalize on what we believe to be significant mass market opportunities. It is a hugely exciting time for the company."

To register for the Nu.Q® Vet Commercial Strategy webinar click HERE. The event will be recorded and available afterwards on-demand.

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com.

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases, in both humans and other animals, including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. This website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's estimated market opportunity, the effectiveness of Volition's blood-based diagnostic, prognostic and disease monitoring tests, and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/volition-to-take-part-in-nuq-vet-commercial-strategy-webinar-301726825.html

SOURCE VolitionRx Limited

Volition to Take Part in Nu.Q® Vet Commercial Strategy Webinar